GlassScriptPhysician profile
Dee L Hubbard
NPI 1295828754
$546.83
in general payments reported to CMS, 2019-2025
13 companies · $91.10 in 2025
The $91.10 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2023: $24.75 · 2024: $141 · 2025: $91.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $167.93 | 2019-2025 | Veozah |
| Abbvie INC. | $82.83 | 2019-2023 | |
| Allergan, INC. | $76.04 | 2019 | |
| Therapeuticsmd, INC. | $38.62 | 2019 | |
| Sage Therapeutics, LLC | $31.86 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.54 | 2019 | |
| Coopersurgical, INC. | $24.65 | 2019 | |
| Organon LLC | $20.83 | 2024 | |
| Exeltis, USA INC. | $18.66 | 2025 | Slynd |
| Mayne Pharma Commercial LLC | $15.66 | 2024 | |
| Avion Pharmaceuticals | $15.46 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.22 | 2019 | |
| Pfizer INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dee Hubbard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.